This breast cancer subtype is managed by surgery, radiation therapies, lowering body hormone levels, or drugs, such as tamoxifen, toremifene, and fulvestrant, to degrade or block the ER and PR receptors on cancer cells attaching to the ER and PR hormones. This evidence concerns the gene ESR1 and breast carcinoma.